U) 7.083 2.576-14.621 Selleckchem CB-839 <0.0001 4.739 1.872-12.053 <0.0001 Age (>65 vs. ≦65) 1.241 0.768-5.724 0.7931       Sex (Male vs. Female) 0.926 0.753-3.761 0.8541       Number (Multiple vs. Single) 1.411 0.674-12.653 0.7244       Size (>3 cm vs. ≤3 cm) 1.537 0.687-10.431 0.7196       Grade (G3 vs. G1/G2) 5.067 1.933-10.763 0.0006 2.055 1.644-8.431 0.0137 Stage (T1 vs. Ta) 2.073 1.027-9.754 0.0176 1.371 0.824-6.084 0.0735 HR: AG-120 concentration Hazard Ratio; M: Methylated; U: unmethylated. Table 4 The predictive value of PCDH8 methylation for the progression-free survival in non muscle invasive bladder cancer (n = 233) Variable Univariate analysis Multivariate analysis HR 95% CI P HR 95% CI P PCDH8 methylation

(M vs. U) 4.893 1.872-9.433 Pexidartinib purchase <0.0001 2.523 1.654-7.431 0.0036 Age (>65 vs. ≦65) 0.896 0.873-5.215 0.8614       Sex (Male vs. Female) 1.213 0.855-5.217 0.5461       Number (Multiple vs. Single) 1.322 0.729-8.537 0.4668       Size (>3 cm vs. ≤3 cm) 1.227 0.579-11.460 0.4962       Grade (G3 vs. G1 / G2) 3.679 1.463-7.754 0.0017 1.874 1.237-6.873 0.0233 Stage (T1 vs. Ta) 1.625 0.893-6.792 0.0614       HR: Hazard Ratio; M: Methylated; U: Unmethylated.

Table 5 The predictive value of PCDH8 methylation for the five-year overall survival in non muscle invasive bladder cancer (n = 233) Variable Univariate analysis Multivariate analysis HR 95% CI P HR 95% CI P PCDH8 methylation (M vs. U) 4.653 1.237-7.314 <0.0001 3.017 1.542-8.251 0.0015 Age (>65 vs. ≦65) 1.135 0.779-6.273 0.3471       Sex (Male vs. Female) 0.874 0.645-3.228 0.7361       Number (Multiple vs. Single) 1.054 0.798-6.417 0.3784       Size (>3 cm vs. ≤3 cm)

1.253 0.913-10.257 0.3095       Grade (G3 vs. G1 / G2) 3.876 1.643-6.024 0.0021 1.852 1.144-5.964 0.0324 Stage (T1 vs. Ta) 1.015 0.792-7.572 0.4338 Selleck Erlotinib       HR: Hazard Ratio; M: Methylated; U: Unmethylated. Discussion Bladder cancer is a multifaceted disease with clinical outcome difficult to predict, and the morphological similar tumors can behave differently [2]. Thus, new biomarkers are needed to predict the outcome of bladder cancer, in addition to commonly used clinicopathological parameters [2]. In recent years, more and more researchers are interested in the aberrant methylation of different genes in bladder cancer for some reasons [9,10,26]. Firstly, aberrant methylation in the promoter regions of the tumor suppressor genes at CPG islands has been recognized as one of the hallmarks of human cancers and associated with silence of gene expression, which may be used as potential biomarker in human cancers [27-31]. Secondly, DNA methylation can be reversed by demethylating agents, which may used as effective therapeutic target. PCDH8 is a novel tumor suppressor gene, and commonly inactivated by aberrant promoter methylation in human cancers [11-16].